Clinical Trial Update: A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the safety and immunogenicity of four doses of the MenACWY conjugate vaccine given with routine vaccines in 2-month-old infants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• Menveo (MenACWY conjugate vaccine) (MenACWY conjugate vaccine)

Snippet

Sponsor: Novartis Vaccines | Conditions: Meningococcal Disease | Phase 3 | Status: COMPLETED | Results posted: 2014-03-26